Cohort characteristics among patients with preoperative diagnosis of endometrial intraepithelial neoplasia from 2010 to 2020
| Characteristics | All patients (n=378) | Final pathology | P value | |
| Endometrial cancer (n=103) | Endometrial intraepithelial neoplasia (n=275) | |||
| Age at presentation (years) | 55 (48–62) | 59 (51–64) | 54 (48–61) | 0.003 |
| Self-reported race | 0.02 | |||
| White | 280 (74) | 85 (83) | 195 (71) | |
| Black/African American | 39 (10) | 3 (3) | 36 (13) | |
| Asian | 30 (8) | 9 (9) | 21 (8) | |
| Unknown | 29 (8) | 6 (6) | 23 (8) | |
| Self-reported ethnicity | 0.54 | |||
| Hispanic or Latinx | 20 (5) | 5 (5) | 15 (5) | |
| Not Hispanic or Latinx | 306 (81) | 87 (84) | 219 (80) | |
| Unknown | 52 (14) | 11 (11) | 41 (15) | |
| Gravidity | 2 (0–3) | 2 (1–3) | 2 (0–3) | 0.10 |
| Parity | 1 (0–2) | 2 (0–2) | 1 (0–2) | 0.17 |
| Body mass index (kg/m2) | 0.58 | |||
| <30 | 110 (29) | 26 (25) | 84 (31) | |
| 30–39.9 | 139 (37) | 41 (40) | 98 (36) | |
| 40–49.9 | 92 (24) | 23 (22) | 69 (25) | |
| 50–59.9 | 34 (9) | 12 (12) | 22 (8) | |
| 60–69.9 | 1 (0.3) | – | 1 (0.4) | |
| ≥70 | 2 (1) | 1 (1) | 1 (0.4) | |
| Tobacco use (current or former)§ | 75 (20) | 23 (22) | 52 (19) | 0.46 |
| Hypertension§ | 210 (56) | 67 (65) | 143 (52) | 0.02 |
| Type II diabetes mellitus§ | 81 (21) | 24 (23) | 57 (21) | 0.59 |
| Known exposures* | ||||
| Selective estrogen receptor modulator | 14 (4) | 3 (3) | 11 (4) | 0.39 |
| Hormone replacement therapy | 17 (5) | 5 (5) | 12 (5) | 0.50 |
| Oral contraceptives | 67 (18) | 17 (17) | 50 (18) | 0.09 |
| Family history of cancer | ||||
| None | 136 (36) | 45 (44) | 91 (33) | 0.06 |
| Breast | 128 (34) | 29 (28) | 99 (36) | 0.15 |
| Uterine | 31 (8) | 3 (3) | 28 (10) | 0.02 |
| Ovarian | 34 (9) | 8 (8) | 26 (9) | 0.61 |
| Colon | 68 (18) | 9 (9) | 59 (21) | 0.004 |
| Other | 74 (20) | 17 (17) | 57 (21) | 0.36 |
| Unknown | 19 (5) | 8 (8) | 11 (4) | 0.14 |
| ASA class† | 0.70 | |||
| 1 | 13 (3) | 3 (3) | 10 (4) | |
| 2 | 183 (48) | 47 (46) | 136 (49) | |
| 3 | 163 (43) | 45 (44) | 118 (43) | |
| 4 | 4 (1) | 1 (1) | 3 (1) | |
| Endometrial stripe thickness, by US (mm)‡§ | 12 (8–17) | 14 (10–19) | 11 (8–16) | 0.002 |
Data presented as n (%) or median (interquartile range).
*No minimum length of exposure required.
†ASA class, American Society of Anesthesiologists physical status classification system.
‡Missing 68 values (20 in endometrial cancer group and 48 in benign pathology group).
§Percentage calculations exclude missing data.